为肝细胞癌武装 GPC3 CAR-T 细胞:多少才足够,下一步是什么?
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt.
The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
HCC 是一种异质性肿瘤,具有多样的临床、病理和预后参数。在 HCC 患者的治疗决策中,结合特定亚型的临床病理特征至关重要。
肝细胞癌(HCC)尽管出现了多种预防和治疗手段,仍然是一个主要的健康问题。HCC具有异质性和广泛的形态分子模式,导致独特的临床和预后标准。因此,我们旨在研究HCC的临床和病理标准,以更新形态分子分类,并为该疾病的诊断提供指导。
本研究纳入530例经病理分析的HCC病例。收集了这些病例的临床和生存数据。
丙型肝炎病毒仍是埃及HCC的主要原因。与干扰素相关HCC相比,直接抗病毒药物后HCC表现出侵袭性病程。高龄、男性、甲胎蛋白水平升高、肿瘤大小和背景肝脏是重要的预后参数。特殊HCC变异型具有特征性的临床、实验室、影像学、预后和生存数据。TIL(肿瘤浸润淋巴细胞)而非中性粒细胞富集型HCC具有极好的预后。
Hepatocellular carcinoma (HCC) remains a major health problem despite the emergence of several preventive and therapeutic modalities. HCC has heterogeneous and wide morpho-molecular patterns, resulting in unique clinical and prognostic criteria. Therefore, we aimed to study the clinical and pathological criteria of HCC to update the morpho-molecular classifications and provide a guide to the diagnosis of this disease.
Five hundred thirty pathologically analyzed HCC cases were included in this study. The clinical and survival data of these cases were collected.
Hepatitis C virus is still the dominant cause of HCC in Egypt. Post-direct-acting antiviral agent HCC showed an aggressive course compared to interferon-related HCC. Old age, male gender, elevated alpha-fetoprotein level, tumor size, and background liver were important prognostic parameters. Special HCC variants have characteristic clinical, laboratory, radiological, prognostic, and survival data. Tumor-infiltrating lymphocytes rather than neutrophil-rich HCC have an excellent prognosis.
HCC is a heterogenous tumor with diverse clinical, pathological, and prognostic parameters. Incorporating the clinicopathological profile per specific subtype is essential in the treatment decision of patients with HCC. TRIAL REGISTRATION: This was a retrospective study that included 530 HCC cases eligible for analysis. The cases were obtained from the archives of the Pathology Department, during the period between January 2010 and December 2019. Clinical and survival data were collected from the patients' medical records after approval by the institutional review board (IRB No. 246/2021) of Liver National Institute, Menoufia University. The research followed the guidelines outlined in the Declaration of Helsinki and registered on ClinicalTrials.gov (NCT05047146).
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。